We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Review
Sequential use of biologic therapy in rheumatoid arthritis.
Current Opinion in Rheumatology 2010 May
PURPOSE OF REVIEW: With an increasing range of biological therapies available in the management of rheumatoid arthritis, sequencing of such therapies is becoming more frequent, particularly with more ambitious treatment aims. This review will address the evidence to date on use of successive targeted agents.
RECENT FINDINGS: Double-blind, randomized controlled trials have confirmed the role of alternative tumour necrosis factor (TNF) inhibitors (TNFi), rituximab, abatacept and tocilizumab, following TNFi failure with no comparative studies to date. Registry data have demonstrated efficacy of switching from a first to a second TNFi. Observational experience has confirmed benefits of switching from TNFi to TNFi and TNFi to rituximab. Within available randomized controlled trial data, tocilizumab appears effective in TNFi failure group, irrespective of number of TNFi previously failed. Such data are not available for the other agents. No safety signals have been identified thus far with biologic sequencing. Although formal comparative, controlled studies do not exist, type of previous failure to TNFi and disease characteristics (serology, comorbidity, concomitant therapy) can provide a good platform for choosing the next biologic treatment.
SUMMARY: Although biological sequencing is well established, optimal approach represents a significant knowledge gap; well designed clinical studies with associated mechanistic investigation are necessary to identify disease subgroups that would benefit from one sequence over another.
RECENT FINDINGS: Double-blind, randomized controlled trials have confirmed the role of alternative tumour necrosis factor (TNF) inhibitors (TNFi), rituximab, abatacept and tocilizumab, following TNFi failure with no comparative studies to date. Registry data have demonstrated efficacy of switching from a first to a second TNFi. Observational experience has confirmed benefits of switching from TNFi to TNFi and TNFi to rituximab. Within available randomized controlled trial data, tocilizumab appears effective in TNFi failure group, irrespective of number of TNFi previously failed. Such data are not available for the other agents. No safety signals have been identified thus far with biologic sequencing. Although formal comparative, controlled studies do not exist, type of previous failure to TNFi and disease characteristics (serology, comorbidity, concomitant therapy) can provide a good platform for choosing the next biologic treatment.
SUMMARY: Although biological sequencing is well established, optimal approach represents a significant knowledge gap; well designed clinical studies with associated mechanistic investigation are necessary to identify disease subgroups that would benefit from one sequence over another.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app